Vinpocetine

Psychostimulants and nootropics. Other psychostimulants and nootropics

ATC code: N06BX18

Brand names: Vinpocetine, Cavinton

Updated 2 Jun 2026 · Methodology

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

Chronic cerebrovascular insufficiency

Not recommended

Evidence tier F. The diagnostic entity "chronic cerebrovascular insufficiency" used to justify vinpocetine in Russian practice is absent from international classifications; international neurology uses vascular cognitive impairment and vascular dementia. The 2003 Cochrane review found no convincing efficacy. , and guidelines do not list vinpocetine for cerebrovascular disease. The 2019 safety communication added a pregnancy harm signal that further narrows any acceptable risk-benefit window.

Sources

ICD-10: I67.8 · ICD-11: 8B22

Memory and concentration enhancement

Not recommended

Vinpocetine is a derivative of vincamine (a periwinkle alkaloid) sold in Russia and several Eastern European countries as a brain circulation and memory enhancement agent. In 2019 the explicitly excluded vinpocetine from the dietary supplement category and warned of pregnancy-loss risk in women of reproductive age. International clinical guidelines (, , Alzheimer's Association) do not include vinpocetine. For memory complaints in older adults, the evidence-based approach is blood-pressure control, lipid management, smoking cessation, physical activity, cognitive training, depression screening, and review of medication side effects. If vinpocetine was prescribed for memory or vascular support, consider seeking a second opinion.

Sources

AAN: Practice guideline update summary: Pharmacologic treatment for migraine prevention in children and adolescents (2019)

Vascular dementia

Not recommended

Evidence tier F. The 2003 Cochrane review on vinpocetine in dementia (Szatmari and Whitehouse) included three RCTs and found no clinically meaningful effect on cognition, global outcome or quality of life, with insufficient evidence to support routine use. No subsequent high-quality RCT has changed this picture. The 2018 practice guideline on mild cognitive impairment and international dementia guidelines (EAN 2020, NG97) do not list vinpocetine. Vascular dementia management focuses on aggressive vascular risk factor control, antiplatelet therapy after non-cardioembolic stroke and structured cognitive rehabilitation.

Sources

ICD-10: F01 · ICD-11: 6D81

Vertigo, unspecified

Not recommended

Evidence tier F. Vinpocetine has no evidence base in vertigo. International vertigo guidelines (Barany Society, -HNS 2017 BPPV update) do not mention the drug. Vertigo requires targeted diagnosis: canalith repositioning for benign paroxysmal positional vertigo, vestibular suppressants short-term plus vestibular rehabilitation for vestibular neuritis, betahistine and dietary measures for Meniere disease, treatment of underlying psychiatric condition for persistent postural-perceptual dizziness. Generic "vasoactive" prescribing for "dizziness" delays the correct workup.

Sources

Cochrane: Vinpocetine for cognitive impairment and dementia (2003)

ICD-10: R42 · ICD-11: MB48.0

How to read tiers A–F

AStrong evidence – first or second line in international guidelines
BRecommended in selected cases
CStudy data contradict each other
DBenefit not proven, no documented harm
FDocumented harm, or risk without benefit

Mechanism of action

Vinpocetine is a semisynthetic ethyl ester of apovincamine derived from vincamine, an alkaloid of the lesser periwinkle (Vinca minor). Proposed mechanisms include voltage-gated sodium channel blockade, phosphodiesterase 1 inhibition, increased cerebral blood flow and antioxidant activity in laboratory preparations. Clinical translation of these effects to cognitive or cerebrovascular outcomes has not been confirmed in adequately powered modern RCTs. Vinpocetine is registered as a prescription drug in Russia, the EAEU, Hungary, Germany and several other European countries, but the has not granted a centralised authorisation. The MHRA has not approved it in the United Kingdom. In 2019 the explicitly removed vinpocetine from the dietary supplement category in the United States and issued a safety communication warning of miscarriage risk in pregnancy.

Safety

Boxed warning

FDA boxed warning is not applicable (the drug is not registered as a medicine in the US). In 2019 the FDA issued a separate warning on the risk of miscarriage and adverse fetal outcomes from vinpocetine use by women of reproductive age.

Contraindications

Pregnancy – risk of miscarriage and adverse fetal outcomes (FDA 2019 warning)
Breastfeeding
Age under 18 (insufficient data)
Acute phase of hemorrhagic stroke
Significant cardiac arrhythmias
Severe ischemic heart disease
Hypersensitivity to drug components

Serious adverse effects

Miscarriage and adverse fetal outcomes (FDA 2019)
Severe hypotension
Life-threatening arrhythmias (rare)
Anaphylactic reactions

Common adverse effects

Blood pressure reduction
Tachycardia, ectopic beats
Headache, dizziness
Nausea, heartburn
Drowsiness or insomnia

Uncommon adverse effects

Rash, pruritus
ALT/AST elevation
Thrombocytopenia

Pregnancy: can you take Vinpocetine?

Contraindicated in pregnancy. The FDA in 2019 explicitly warned of miscarriage and adverse fetal outcome risk. In women of reproductive age, use is acceptable only with reliable contraception; when pregnancy is planned, the drug is discontinued.

Breastfeeding: can you take Vinpocetine?

Data on transfer into breast milk are limited. Breastfeeding is interrupted during use.

Calculate RID

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Practical notes

Evidence

In most countries, vinpocetine is not used in clinical practice – there is no evidence base. The drug remains in the registers of post-Soviet countries as a legacy of older regulatory decisions. It is not -registered in the US; the has not approved it; it is not used in the UK, Germany, Canada or Australia. Before prescribing, openly discuss the limitations of the evidence with the patient.

Alternatives

For the complaints prompting vinpocetine prescriptions, an evidence-based strategy includes: vascular risk factor assessment (BP, lipids, glucose, atrial fibrillation), depression and anxiety screening (, GAD-7), neuropsychological evaluation and brain MRI if cerebrovascular disease is suspected. For confirmed diagnoses – targeted therapy (antihypertensives, statins, antiplatelet agents on indication, cholinesterase inhibitors and memantine in dementia).

Special situations

If a patient is already on vinpocetine and insists on continuing, consider: objective evaluation of real clinical effect by validated scales, search for alternatives with proven efficacy, open discussion of the evidence limitations. Abrupt withdrawal does not produce a withdrawal syndrome; transition to non-pharmacological methods and targeted therapy is over 2–4 weeks.

Common myths

Myth: «Cavinton improves cerebral blood flow». Fact: in experimental models a local blood flow increase is observed, but clinical outcomes (stroke prevention, cognitive improvement, mortality reduction) are not demonstrated.

Myth: «Cavinton is time-tested, therefore it works». Fact: market longevity is not evidence of efficacy. Modern RCT criteria apply to old drugs as well, and vinpocetine does not meet them.

Myth: «Cavinton is as safe as a dietary supplement». Fact: the in 2019 explicitly removed vinpocetine from the dietary supplement category and warned of miscarriage risk.

Label mentions10 mentions

Verbatim lines from the interaction sections, in the language of the label

From this drug’s label

Majorantiagregantesclass named in the label
«Debido a que la vinpocetina disminuye la agregación plaquetaria, debe evitarse en pacientes en tratamiento con medicamentos antiagregantes o anticoagulantes. Por lo tanto, debe evitarse la…»
AEMPS, section 4.5 · Open on CIMA
Majoranticoagulantesclass named in the label
«Debido a que la vinpocetina disminuye la agregación plaquetaria, debe evitarse en pacientes en tratamiento con medicamentos antiagregantes o anticoagulantes. Por lo tanto, debe evitarse la…»
AEMPS, section 4.5 · Open on CIMA
MajorClopidogrel
«Debido a que la vinpocetina disminuye la agregación plaquetaria, debe evitarse en pacientes en tratamiento con medicamentos antiagregantes o anticoagulantes. Por lo tanto, debe evitarse la…»
AEMPS, section 4.5 · Open on CIMA
MajorDiclofenac
«Debido a que la vinpocetina disminuye la agregación plaquetaria, debe evitarse en pacientes en tratamiento con medicamentos antiagregantes o anticoagulantes. Por lo tanto, debe evitarse la…»
AEMPS, section 4.5 · Open on CIMA
MajorIbuprofen
«Debido a que la vinpocetina disminuye la agregación plaquetaria, debe evitarse en pacientes en tratamiento con medicamentos antiagregantes o anticoagulantes. Por lo tanto, debe evitarse la…»
AEMPS, section 4.5 · Open on CIMA
MajorNaproxen
«Debido a que la vinpocetina disminuye la agregación plaquetaria, debe evitarse en pacientes en tratamiento con medicamentos antiagregantes o anticoagulantes. Por lo tanto, debe evitarse la…»
AEMPS, section 4.5 · Open on CIMA
MajorWarfarin
«Debido a que la vinpocetina disminuye la agregación plaquetaria, debe evitarse en pacientes en tratamiento con medicamentos antiagregantes o anticoagulantes. Por lo tanto, debe evitarse la…»
AEMPS, section 4.5 · Open on CIMA
ModerateAINEclass named in the label
«In vitro la vinpocetina tiene un efecto inhibidor débil sobre el CYP2C9. No existen estudios de interacción in vivo sobre el efecto de esta inhibición sobre la farmacocinética de otros fármacos, por…»
AEMPS, section 4.5 · Open on CIMA
Moderateantiarrítmicosclass named in the label
«No se puede descartar la existencia de interacción con medicamentos antihipertensivos o antiarrítmicos. Por ello debe controlarse estrechamente a los pacientes tratados concomitantemente con…»
AEMPS, section 4.5 · Open on CIMA
ModeratePhenytoin
«In vitro la vinpocetina tiene un efecto inhibidor débil sobre el CYP2C9. No existen estudios de interacción in vivo sobre el efecto de esta inhibición sobre la farmacocinética de otros fármacos, por…»
AEMPS, section 4.5 · Open on CIMA

Check interaction with another drug

Opens the checker prefilled with this drug. Pick the second one from your regimen.

Open checker

Summary of a multi-drug list →

Medicine list: everything you take in one place →

Frequently asked

What is Vinpocetine used for?

Vinpocetine is evaluated for the following indications with varying evidence strength: Vertigo, unspecified (evidence tier F), Vascular dementia (evidence tier F), Chronic cerebrovascular insufficiency (evidence tier F). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Vinpocetine?

Common side effects of Vinpocetine (≥ 1 in 100): Blood pressure reduction, Tachycardia, ectopic beats, Headache, dizziness, Nausea, heartburn, Drowsiness or insomnia. See the Safety section for uncommon and serious reactions.

Is Vinpocetine safe during pregnancy?

Is Vinpocetine compatible with breastfeeding?

Data on transfer into breast milk are limited. Breastfeeding is interrupted during use.

Who should not take Vinpocetine?

Vinpocetine is contraindicated in: Pregnancy – risk of miscarriage and adverse fetal outcomes (FDA 2019 warning); Breastfeeding; Age under 18 (insufficient data); Acute phase of hemorrhagic stroke; Significant cardiac arrhythmias. Full list in the Safety section.

Does Vinpocetine carry an FDA boxed warning?

Cavinton improves cerebral blood flow

in experimental models a local blood flow increase is observed, but clinical outcomes (stroke prevention, cognitive improvement, mortality reduction) are not demonstrated.

Cavinton is time-tested, therefore it works

market longevity is not evidence of efficacy. Modern RCT criteria apply to old drugs as well, and vinpocetine does not meet them.

Cavinton is as safe as a dietary supplement

the FDA in 2019 explicitly removed vinpocetine from the dietary supplement category and warned of miscarriage risk.

Official sources

Direct links to regulator labels. Open in a new tab.

AEMPS / CIMALabel dated 09/16/2020
GRLS

Other drugs in this group

Vortioxetine, 5-hydroxytryptophan (5-HTP), Agomelatine, Amitriptyline, Choline bitartrate, Galantamine, Methylphenidate, Piracetam